Skip to main content
SpringerLink
Log in

Assessment of therapy response in malignant tumours with 18F-fluorothymidine

  • Editorial commentary
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Seddon BM, Workman P. The role of functional and molecular imaging in cancer drug development. Br J Radiol 2003;76:S128–38.

    Article  PubMed  CAS  Google Scholar 

  2. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207–14.

    Article  PubMed  CAS  Google Scholar 

  3. Helft PR, Daugherty CK. Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation 10.1200/JCO.2006.05.7125. J Clin Oncol 2006;24:4793–5.

    Article  PubMed  Google Scholar 

  4. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–16.

    Article  PubMed  CAS  Google Scholar 

  5. Canellos GP. Residual masses in lymphoma may not be residual disease [editorial]. J Clin Oncol 1988;6:931–3.

    PubMed  CAS  Google Scholar 

  6. Kumar R, Xiu Y, Potenta S, Mavi A, Zhuang H, Yu JQ, et al. FDG-PET in evaluation of treatment response in patients with gastrointestinal tract lymphomas. J Nucl Med 2004;45:1796–803.

    PubMed  Google Scholar 

  7. Kumar R, Maillard I, Alavi A. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin’s and non-Hodgkin’s lymphomas. Radiol Clin North Am. 2004;42:1083–100.

    Article  PubMed  Google Scholar 

  8. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101–11.

    PubMed  CAS  Google Scholar 

  9. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001;19:2797–803.

    PubMed  CAS  Google Scholar 

  10. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D-glucose,L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993;34:773–9.

    PubMed  CAS  Google Scholar 

  11. Kumar R, Loving V, Chauhan A, Zhuang H, Alavi A. Dual time point imaging and its potential to improve breast cancer diagnosis with F18-fluorodeoxyglucose positron emission tomography. J Nucl Med 2005;46:1819–24.

    PubMed  Google Scholar 

  12. Wells P, Gunn RN, Alison M, Steel C, Golding M, Ranicar AS, et al. Assessment of proliferation in vivo using 2-[11C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Res 2002;62:5698–702.

    PubMed  CAS  Google Scholar 

  13. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [18F]FLT and positron emission tomography. Nat Med 1998;4:1334–6.

    Article  PubMed  CAS  Google Scholar 

  14. Seitz U, Wagner M, Neumaier B, Wawra E, Glatting G, Leder G, et al. Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[18F]fluoro-3′-deoxythymidine ([18F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 2002;29:1174–81.

    Article  PubMed  CAS  Google Scholar 

  15. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210–7.

    PubMed  CAS  Google Scholar 

  16. Barthel H, Perumal M, Latigo J, He Q, Brady F, Luthra SK, et al. The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1protein levels. Eur J Nucl Med Mol Imaging 2005;32:257–63.

    Article  PubMed  CAS  Google Scholar 

  17. Reske SN, Deisenhofer S. Is 3′-deoxy-3′-18F-fluorothymidine a better marker for tumour response than18F-fluorodeoxyglucose? J Nucl Med Mol Imaging 2006;33:S38–43.

    Article  CAS  Google Scholar 

  18. Buck AK, Schirrmeister H, Hetzel M, Von Der Heide M, Halter G, Glatting G, et al. 3-deoxy-3-[18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002;62:3331–4.

    PubMed  CAS  Google Scholar 

  19. Dittmann H, Dohmen BM, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002;29:1462–9.

    Article  PubMed  CAS  Google Scholar 

  20. Oyama N, Ponde DE, Dence C, Kim J, Tai YC, Welch MJ. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 2004;45:519–25.

    PubMed  CAS  Google Scholar 

  21. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 2006;8:36–42.

    Article  PubMed  Google Scholar 

  22. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO. Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005;65:4202–10.

    Article  PubMed  CAS  Google Scholar 

  23. Wieder HA, Geinitz H, Rosenberg R, Lordick F, Becker K, Stahl A, et al. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 2006 Dec 29; [Epub ahead of print].

  24. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007 Mar 2; [Epub ahead of print]. DOI 10.1007/s00259-007-0379-4.

  25. Kenny LM, Vigushin DM, Al-Nahhas A, Osman S, Luthra SK, Shousha S, et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005;65:10104–12.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India

    Rakesh Kumar

Authors
  1. Rakesh Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rakesh Kumar.

Additional information

This editorial commentary refers to the article http://dx.doi.org/10.1007/s00259-007-0379-4.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, R. Assessment of therapy response in malignant tumours with 18F-fluorothymidine. Eur J Nucl Med Mol Imaging 34, 1334–1338 (2007). https://doi.org/10.1007/s00259-007-0446-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-007-0446-x

Search

Navigation